Drugs / SUV2208A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07680257 | Dec 2025 → Dec 2027 expected | cancer | Celest Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SUV2208A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07680257 ↗ |
| Modality | Cell therapy | “autologous humanized anti-claudin18.2 chimeric antigen receptor T cell” NCT07680257 ↗ |
| Route | Intravenous | “SUV2208A, DL1, 2 times, Day 0 and Day 28, IV” NCT07680257 ↗ |